Integrated network pharmacology and molecular dynamics-based computational evaluation of a novel Ganoderma lucidum-derived secondary metabolite as a multi-target therapeutic candidate against hepatocellular carcinoma
Journal of Diversity Studies · 15.06.2026 · 5 (2) · 52-63
DOI: 10.51470/jod.2026.5.2.52 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Diversity Studies, online erschienen am 12.07.2026. Verfasst von Ashok Bhupathi und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) remains one of the leading causes of cancer-related mortality worldwide owing to its molecular heterogeneity, therapeutic resistance, and high recurrence rates, necessitating the discovery of effective multitarget therapeutic agents. In the present study, we investigated the anticancer potential of a novel secondary metabolite, (3Z,3’Z)-N,N’-1,2-Ethanediylbis{4-[3-(2-fluorobenzyl)phenyl]-4-hydroxy-2-oxo-3-butenamide}, identified from the aqueous extract of Ganoderma lucidum using LC–QTOF–MS/MS. An integrated computational strategy incorporating physicochemical characterisation, drug-likeness assessment, ADMET prediction, target prediction, network pharmacology, protein–protein interaction analysis, Gene Ontology and KEGG pathway enrichment, molecular docking, 100 ns molecular dynamics simulations, MM-PBSA binding free-energy calculations, and density functional theory analyses was employed to evaluate its therapeutic potential. The metabolite exhibited favorable drug-like properties, high predicted gastrointestinal absorption, compliance with major drug-likeness rules, and an acceptable safety profile. Network pharmacology identified AKT1, EGFR, MAPK1, PIK3CA, BCL2, TP53, KRAS, MYC, BRAF, and VEGFA as key hub genes implicated in HCC progression. Functional enrichment analysis indicated significant modulation of the PI3K/AKT, MAPK, p53, apoptosis, and cell-cycle signaling pathways. Molecular docking demonstrated strong binding affinities toward AKT1 (−8.7 kcal/mol), EGFR (−8.3 kcal/mol), PIK3CA (−8.1 kcal/mol), MAPK1 (−7.9 kcal/mol), and BCL2 (−7.6 kcal/mol), while molecular dynamics and MM-PBSA analyses confirmed stable interactions, with PIK3CA, AKT1, and EGFR exhibiting the most favourable binding free energies. Collectively, these findings identify this G. lucidum-derived metabolite as a promising multitarget candidate for HCC therapy and provide a strong foundation for future experimental and preclinical validation.
Zitieren
APA
Bhupathi, A., & Devamma, M. N. (2026). Integrated network pharmacology and molecular dynamics-based computational evaluation of a novel Ganoderma lucidum-derived secondary metabolite as a multi-target therapeutic candidate against hepatocellular carcinoma. Journal of Diversity Studies, 5(2), 52-63. https://doi.org/10.51470/jod.2026.5.2.52
Vancouver
Bhupathi A, Devamma MN. Integrated network pharmacology and molecular dynamics-based computational evaluation of a novel Ganoderma lucidum-derived secondary metabolite as a multi-target therapeutic candidate against hepatocellular carcinoma. Journal of Diversity Studies. 2026;5(2):52-63. doi:10.51470/jod.2026.5.2.52
BibTeX
@article{Bhupathi2026,
author = {Bhupathi, Ashok and Devamma, M. Nagalakshmi},
title = {Integrated network pharmacology and molecular dynamics-based computational evaluation of a novel Ganoderma lucidum-derived secondary metabolite as a multi-target therapeutic candidate against hepatocellular carcinoma},
journal = {Journal of Diversity Studies},
year = {2026},
volume = {5},
number = {2},
pages = {52--63},
doi = {10.51470/jod.2026.5.2.52}
}
EUVIMED